Search results for "Primary central nervous system lymphoma"

showing 6 items of 6 documents

Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation

2013

High-dose chemotherapy followed by autologous stem cell transplantation has been shown to be feasible and highly effective in newly diagnosed primary central nervous system lymphoma. In this retrospective multicenter study, we investigated prognosis and baseline risk factors in patients with primary central nervous system lymphoma who underwent this treatment approach. We retrospectively analyzed 105 immunocompetent patients with primary central nervous system lymphoma who underwent high-dose chemotherapy followed by autologous stem cell transplantation with or without whole brain radiotherapy as first-line consolidation treated at 12 German centers between 1997 and 2011. We estimated survi…

AdultMaleOncologymedicine.medical_specialtyLymphomamedicine.medical_treatmentAntineoplastic AgentsHematopoietic stem cell transplantationTransplantation AutologousCentral Nervous System NeoplasmsYoung AdultAutologous stem-cell transplantationRisk FactorsMedian follow-upInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineAgedRetrospective StudiesChemotherapyRadiotherapyPerformance statusbusiness.industryHematopoietic Stem Cell TransplantationPrimary central nervous system lymphomaHematologyMiddle AgedPrognosismedicine.diseaseCombined Modality TherapySurgeryTransplantationRadiation therapyTreatment OutcomeFemaleOriginal Articles and Brief ReportsbusinessHaematologica
researchProduct

MYD88 L265P mutation and interleukin‐10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central …

2021

Reliable biomarkers are needed to avoid diagnostic delay and its devastating effects in patients with primary central nervous system (CNS) lymphoma (PCNSL). We analysed the discriminating sensitivity and specificity of myeloid differentiation primary response (88) (MYD88) L265P mutation (mut-MYD88) and interleukin-10 (IL-10) in cerebrospinal fluid (CSF) of both patients with newly diagnosed (n = 36) and relapsed (n = 27) PCNSL and 162 controls (118 CNS disorders and 44 extra-CNS lymphomas). The concordance of MYD88 mutational status between tumour tissue and CSF sample and the source of ILs in PCNSL tissues were also investigated. Mut-MYD88 was assessed by TaqMan-based polymerase chain reac…

AdultMalePathologymedicine.medical_specialtyLymphomaBiopsyConcordanceinterleukin-10diffuse large B-cell lymphomaMutation MissenseCentral Nervous System Neoplasms03 medical and health sciencesprimary CNS lymphoma0302 clinical medicineCerebrospinal fluidhemic and lymphatic diseasesBiopsyBiomarkers TumorTaqManmedicineHumansdiffuse large B-cell lymphoma interleukin-10 interleukin-6 MYD88 L265P mutation primary CNS lymphomaProspective cohort studyAgedmedicine.diagnostic_testbusiness.industryinterleukin-6Primary central nervous system lymphomaHematologyMiddle Agedmedicine.diseaseInterleukin-10Neoplasm ProteinsLymphomaMYD88 L265P mutationAmino Acid Substitution030220 oncology & carcinogenesisMyeloid Differentiation Factor 88FemalebusinessDiffuse large B-cell lymphoma030215 immunologyBritish Journal of Haematology
researchProduct

High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)

2017

Leukemia : normal and malignant hemopoiesis 31(4), 846-852 (2017). doi:10.1038/leu.2016.334

MaleCancer Researchmedicine.medical_specialtyLymphomaPopulationMedizinProcarbazineGastroenterologyCentral Nervous System Neoplasms03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansImmunologic FactorseducationAgedNeoplasm StagingProportional Hazards ModelsAged 80 and overeducation.field_of_studyHematologybusiness.industryRemission InductionPrimary central nervous system lymphomaHematologyLomustinemedicine.diseaseSurgeryTumor BurdenMethotrexateTreatment OutcomeOncology030220 oncology & carcinogenesisCytarabineQuality of LifeMethotrexateRituximabOriginal ArticleFemalebusiness030215 immunologymedicine.drugLeukemia
researchProduct

Elimination of Established Risk-Factors in Primary Central Nervous System Lymphoma - Impact of High-Dose Chemotherapy Followed by Autologous Stem-Cel…

2011

Abstract Abstract 3089 Introduction: High-dose chemotherapy (HDT) and autologous stem-cell transplantation (ASCT) demonstrated high efficacy in the treatment of newly-diagnosed primary CNS lymphoma (PCNSL) in eligible patients (pts). Prognosis of PCNSL is associated with several clinical and histopathological risk factors (RF). Early complete response (CR) during chemotherapy (CHT) was recently reported to be an additional independent prognostic factor in pts undergoing polychemotherapy without HDT+ASCT. In this analysis, we examined the extent to which known RF determined survival in pts who were treated with HDT-ASCT. We additionally investigated the impact of HDT-ASCT specific factors (e…

Oncologymedicine.medical_specialtyChemotherapyPerformance statusbusiness.industryProportional hazards modelmedicine.medical_treatmentImmunologyPrimary central nervous system lymphomaCell BiologyHematologyThioTEPAmedicine.diseaseBiochemistryChemotherapy regimenSurgeryTransplantationInternal medicineMedicineStem cellbusinessmedicine.drugBlood
researchProduct

Image Analysis of Proliferating Cells in Tumors of the Human Nervous System

1994

Obtaining growth fractions from immunohistological preparations by the commonly used cell count calculation method is time consuming. For the first time, we investigated and compared the detection of proliferating cells in immunohistologically labeled tissue from tumors of the nervous system using the monoclonal antibody Ki-67 by a new computerized image analysis system and by cell count calculation. The two methods showed a high correlation (correlation index, 0.98) in 37 gliomas (2 pilocytic astrocytomas, 10 Grade II astrocytomas, 5 Grade III astrocytomas, 20 Grade IV astrocytomas and glioblastoma multiforme) and a heterogenous group of 10 additional tumors of the nervous system, includin…

PineoblastomaPathologymedicine.medical_specialtybiologybusiness.industryPrimary central nervous system lymphomaAstrocytomamedicine.diseaseKi-67GliomaImmunologymedicinebiology.proteinNeurofibromaSurgeryNeurology (clinical)OligodendrogliomabusinessAnaplastic astrocytomaNeurosurgery
researchProduct

CT and MR Imaging of Non-neoplastic Intracranial Masses

1989

Many intracranial mass lesions of non-neoplastic origin present CT and MR features similar or identical to those of true neoplasms. In many cases a definitive diagnosis cannot be made from imaging findings alone, and misinterpretation is possible even when the history and clinical findings are considered. Yet an accurate preoperative diagnosis is an essential prerequisite for selecting candidates for a neurosurgical operation and planning the procedure. In some cases the full range of neuroradiologic techniques may have to be applied and evaluated in the context of clinical findings before the physician can accurately classify the disease and draw appropriate therapeutic conclusions.

medicine.medical_specialtyNon neoplasticbusiness.industryProgressive multifocal leukoencephalopathyPrimary central nervous system lymphomaContext (language use)medicine.diseaseMr imagingArachnoid cystmedicineRadiologybusinessBrain abscessIntracranial mass
researchProduct